Screener / SEC EDGAR /CIK 0001384101 /10-K filed Feb 26, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Labs

Veracyte, Inc. VCYT

Compare with peers Embed
Earnings releases

Latest results release: Nov 4, 2026

8-K item 2.02, exhibit 99

What VCYT's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 4, 2026 · EX-99.1

Veracyte Announces Third Quarter 2026 Financial Results

Open on SEC

Grew total revenue to $151.8 million and testing revenue to $146.4 million, representing 15% year-over-year growth

Announces $100 million share repurchase program SOUTH SAN FRANCISCO, Calif., November 4, 2026 --- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the third quarter ended September 30, 2026.

“We delivered solid third quarter results supported by strong profitability and cash generation,” said Marc Stapley, chief executive officer of Veracyte. “Afirma outperformed, while Decipher Prostate volume was below our expectations. We remain confident in the long-term outlook of our business and expect a number of evidence-based catalysts to support growth in our core franchises while also advancing our breast and bladder strategies. As we execute on these opportunities, our differentiated financial profile enables us to continue investing in the business to drive long-term growth.”

For the three-month period ended September 30, 2026, as compared to the same period in 2025: • Increased total revenue by 15% to $151.8 million and testing revenue by 15% to $146.4 million, driven by Decipher Prostate growth of 12% to $92.3 million and Afirma growth of 19% to $51.5 million.

• Increased total volume by 15% to 52,744 tests and testing volume by 13% to 49,498 tests, driven by approximately 29,900 Decipher Prostate tests, as well as approximately 19,100 Afirma tests. Volume for each test grew 12% year-over-year.

• Increased product revenue by 40% to $4.6 million, driven by strong adoption of Prosigna IVD following the release of the phase III OPTIMA trial results at ASCO.

• Recorded GAAP net income of $31.5 million, or 20.8% of revenue, and delivered adjusted EBITDA of $41.2 million, or 27.2% o f revenue.

• Generated $40.3 million of cash from operations to end the quarter with $370.5 million of cash, cash equivalents, and short-term investments as of September 30, 2026.

• Acquired Convergent Genomics, Inc., expanding our urology portfolio with a urinary tumor DNA testing platform to help guide bladder cancer care across the patient journey.

• Secured Medicare reimbursement for our Prosigna Breast Risk of Recurrence (ROR) test in the U.S. for eligible patients diagnosed with early-stage hormone- receptor positive (HR+) breast cancer.

• Further expanded the clinical evidence of the Decipher Prostate test, with new predictive evidence supporting its use with treatment intensification decisions across intermediate-risk and very high-risk prostate cancer.

• Surpassed a key milestone, with more than 1 million patients served to date with Veracyte's tests.

• Announced that the Board of Directors has authorized a share repurchase program for up to $100 million of common stock.

A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release. An explanation of these measures is also included below under the heading "Note Regarding Use of Non-GAAP Financial Measures."

Total revenue for the third quarter of 2026 was $151.8 million, an increase of 15% compared to $131.9 million reported in the third quarter of 2025. Testing revenue was $146.4 million, an increase of 15% compared to $127.8

million in the third quarter of 2025, driven by growth in our Decipher Prostate and Afirma tests. Product revenue was $4.6 million, an increase of 40% compared to $3.3 million in the third quarter of 2025, driven by strong adoption of Prosigna IVD following the release of the phase III OPTIMA trial results at ASCO. Biopharmaceutical and other revenue was $0.7 million, compared to $0.8 million in the third quarter of 2025.

Total gross margin for the third quarter of 2026 was 71%, compared to 69% in the third quarter of 2025. Non-GAAP gross margin was 74%, compared to 73% in the third quarter of 2025.

Operating expenses were $90.5 million for the third quarter of 2026 compared to $68.3 million in the third quarter of 2025. Non-GAAP operating expenses grew 24% to $72.9 million compared to $58.6 million in the third quarter of 2025.

GAAP Net income for the third quarter of 2026 was $31.5 million, an increase of $12.4 million compared to the third quarter of 2025. Diluted net earnings per common share was $0.38, an improvement of $0.14 compared to the third quarter of 2025. Non-GAAP diluted net earnings per common share was $0.51, flat compared to the third quarter of 2025. Net cash provided by operating activities in the first nine months of 2026 was $121.3 million, an improvement of $37.6 million compared to the same period in 2025.

Adjusted EBITDA for the third quarter of 2026 was $41.2 million, an improvement of 4% compared to the third quarter of 2025, representi ng 27.2% of revenue.

Veracyte now expects 2026 total revenue guidance of $590 million to $593 million, representing 14% to 15% growth, compared to prior guidance of $590 million to $596 million. This reflects testing revenue of $571 million to $573 million, representing 16% growth, compared to prior guidance of $576 million to $582 million, with minimal revenue contribution from recently launched tests. Further, the company continues to expect adjusted EBITDA margin of greater than 26% for 2026.

The company is unable to provide a quantitative reconciliation of expected adjusted EBITDA margin to expected GAAP net income margin, the most directly comparable forward-looking GAAP measure without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, that are dependent on various factors, are out of the company’s control, or that cannot be reasonably predicted. Such adjustments include, but are not limited to, acquisition-related expenses, and other adjustments. Any associated estimate of these items and their impact on GAAP performance for the guidance period could vary materially. For more information on the non-GAAP financial measures, please refer to the section titled “Note Regarding Use of Non-GAAP Financial Measures” at the end of this press release.

Veracyte announced today that its Board of Directors has authorized a share repurchase program for up to $100 million of its common stock. Under the repurchase program, the company may repurchase shares through open market purchases, privately negotiated transactions or by other methods from time to time. Any open market repurchases will be structured to comply with applicable federal securities laws, including the pricing and volume requirements of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The timing, manner, price, and amount of any repurchases will be determined at the company's discretion based on a variety of factors, including market conditions, the trading price of the company's common stock, the company's financial condition and results of operations, capital requirements, general business conditions, alternative investment opportunities, and other factors the company deems relevant. The repurchase program does not obligate the company to acquire any specific number of shares, may be modified, suspended, or discontinued at any time without prior notice at the discretion of the Board of Directors, and will expire after 12 months. The company currently expects to fund the repurchase program from available cash and cash equivalents.

Veracyte will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss the company's financial results and provide a general business update. The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media- server.com/mmc/p/kgcmbvpd. The webcast should be accessed 10 minutes prior to the conference call start time. A replay of the webcast will be available for one year following the conclusion of the live broadcast and will be accessible on the company’s website at https://investor.veracyte.com/events-presentations.

Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company’s molecular tests assess the unique biology of each patient’s tumor to help clinicians answer essential questions about cancer care. Veracyte’s Diagnostics Platform combines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continued innovation and pipeline development . The company’s portfolio includes the Afirma® Genomic Sequencing Classifier test , Decipher® Bladder Genomic Classifier test , Decipher® Prostate Genomic Classifier test , Prosigna® Breast Risk of Recurrence test , and the TrueMRD™ Monitoring Test for MIBC . For more information, visit Veracyte’s website or follow the company on LinkedIn or X (Twitter) .

This press release contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, and expectations (financial and otherwise), including with respect to our 2026 financial and operating results; our share repurchase program, including the timing, amount and source of funds for any

repurchases of shares; and our intentions with respect to the development, launch, commercialization, adoption, and reimbursement of our tests and products. Forward-looking statements can be identified by words such as: “appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “could,” “would,” “will,” “enable,” “positioned,” “offers,” “designed,” “ultimately,” “strategic,” “outlook,” “guidance,” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to: our ability to launch, commercialize and receive reimbursement for our products; our ability to execute on our business strategies relating to our acquisitions, including C2i Genomics and Convergent Genomics, Inc., integration of the business and the realization of expected benefits and synergies; our ability to demonstrate the validity and utility of our genomic tests and biopharma and other offerings; our ability to continue executing on our business plan; our ability to continue to scale our global operations and enhance our internal control environment; the impact of the war in Ukraine and other regional conflicts on European economies; the impact of foreign currency fluctuations, volatile interest rates, inflation, the impact of legislation and policies enacted by the current U.S. administration; turmoil in the global banking and finance system; the ongoing conflict in the Middle East; and the performance and utility of our tests in the clinical environment. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 26, 2026, as well as in other documents that we may file from time to time with the Securities and Exchange Commission. Copies of these documents, when available, may be found in the Investors section of our website at investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise.

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this press release and the accompanying tables contain, and reference certain non-GAAP results including non-GAAP gross margin, non-GAAP operating expenses, adjusted EBITDA, adjusted EBITDA as a percentage of revenue (also referred to as adjusted EBITDA margin), non-GAAP net income, and non-GAAP earnings per share (EPS) and non-GAAP weighted average shares outstanding. These non-GAAP financial measures are not meant to be considered superior to or a substitute for financial measures calculated in accordance with GAAP, and investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool.

We use non-GAAP financial measures to internally evaluate and analyze financial results. We believe these non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance, and enable comparison of our financial results with other public companies, many of which present similar non-GAAP financial measures. However, the non-GAAP financial measures we present may be different from those used by other companies, including similarly titled measures.

We compute these non-GAAP measures by adjusting the applicable GAAP measure to remove the impact of certain recurring and non-recurring charges and gains and to adjust for the impact of income tax items related to such adjustments to our GAAP financial statements. In particular, we exclude amortization of acquired intangible assets,

acquisition-related expenses relating to our acquisitions of Decipher Biosciences, HalioDx and C2i Genomics, impairment charges associated with the nCounter license and other biopharmaceutical services related to HalioDx intangible assets, all stock-based compensation and certain costs related to restructuring from all of our non-GAAP financial measures as well as depreciation and income tax items from our adjusted EBITDA and adjusted EBITDA as a percentage of revenue. Beginning in the second quarter of 2024, we changed our non-GAAP policy to exclude all stock-based compensation to align with our peers and we have also excluded all stock-based compensation from our prior period non-GAAP financial measures. Management has excluded the effects of these items in non-GAAP financial measures to help investors gain a better understanding of the core operating results and future prospects of the company, consistent with how management measures and forecasts the company's performance, especially when comparing such results to previous periods or forecasts. The company encourages investors to carefully consider its results under GAAP, together with its supplemental non‐GAAP information and the reconciliation between these presentations. See “Reconciliation of U.S. GAAP to Non-GAAP Financial Measures” for a reconciliation of each non-GAAP measure presented to the comparable GAAP financial measure.

1. Cost of revenue, research and development, sales and marketing and general and administrative expenses include the following stock-based compensation related expenses:

VERACYTE, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) September 30, December 31, Assets 2026 2025 Current assets: (Unaudited) (See Note 1) ────────────────────────────────────────────────────────────────────────────── Cash and cash $ 199,828 $ 362,578 equivalents Short-term 170,704 50,311 investments Accounts receivable 56,788 44,660 Supplies 25,818 20,546 Prepaid expenses and other current 14,740 10,281 assets Total current assets 467,878 488,376 Property, plant and 24,870 22,192 equipment, net Right-of-use assets, 35,097 36,599 operating leases Intangible assets, 184,883 89,148 net Goodwill 855,575 767,154 Restricted cash 1,646 1,648 Other assets 3,307 902 Total assets $ 1,573,256 $ 1,406,019 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 9,710 $ 4,593 Accrued liabilities 60,087 48,801 Current portion of 864 1,160 deferred revenue Current portion of acquisition-related 6,734 1,332 contingent consideration Current portion of operating lease 6,814 4,051 liabilities Total current 84,209 59,937 liabilities Deferred tax 1,616 646 liabilities Acquisition-related contingent 17,245 257 consideration, net of current portion Operating lease liabilities, net of 33,922 35,603 current portion Other liabilities 3,000 — Total liabilities 139,992 96,443 Total stockholders’ 1,433,264 1,309,576 equity Total liabilities and stockholders’ $ 1,573,256 $ 1,406,019 equity 1. The condensed consolidated balance sheet at December 31, 2025 has been derived from the audited financial statements at that date included in the company's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on February 26, 2026.

VERACYTE, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Nine Months Ended (In thousands) September 30, Operating activities 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 85,700 $ 25,204 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and 16,247 16,117 amortization Loss on disposal of property, plant and 367 15 equipment Stock-based 40,806 32,700 compensation Deferred income taxes -11,599 -13 Noncash lease expense 2,088 2,289 Revaluation of acquisition-related -1,110 -2,713 contingent consideration Effect of foreign -23 -3,845 currency on operations Amortization of discount on short-term -2,380 -2,619 investments Impairment loss — 20,505 Non-cash loss on deconsolidation of — 3,863 subsidiary Changes in operating assets and liabilities: Accounts receivable -11,963 -3,858 Supplies -3,435 -2,642 Prepaid expenses and other current -4,112 -6,416 assets Other assets -771 331 Operating lease 496 -1,681 liabilities Accounts payable 5,522 -547 Accrued liabilities 5,466 7,034 and deferred revenue Net cash provided by operating 121,299 83,724 activities Investing activities Business acquisitions, net of cash -153,190 — acquired Purchase of short-term -234,997 -99,998 investments Proceeds from maturity of short-term 116,984 102,116 investments Issuance of loan -1,622 — receivable Purchases of property, plant and -8,155 -5,897 equipment Net cash used in -280,980 -3,779 investing activities Financing activities Payment of taxes on vested restricted -17,462 -14,645 stock units Proceeds from the exercise of common stock options and 14,493 10,572 employee stock purchases Net cash used in -2,969 -4,073 financing activities (Decrease) increase in cash, cash -162,650 75,872 equivalents and restricted cash Effect of foreign currency on cash, cash -102 707 equivalents and restricted cash Net (decrease) increase in cash, cash -162,752 76,579 equivalents and restricted cash Cash, cash equivalents and restricted 364,226 240,631 cash at beginning of period Cash, cash equivalents and restricted $ 201,474 $ 317,210 cash at end of period

CASH, CASH EQUIVALENTS AND RESTRICTED CASH (Unaudited) (In thousands) September 30, December 31, 2026 2025 Cash and cash equivalents $ 199,828 $ 362,578 Restricted cash 1,646 1,648 Total cash, cash equivalents and $ 201,474 $ 364,226 restricted cash

1.Includes transaction-related expenses as well as post-combination compensation expenses. For the three months ended September 30, 2026, adjustments consist primarily of transaction-related expenses associated with the acquisition of Convergent Genomics, Inc. ("Convergent") ($1.7 million) partially offset with contingent consideration related to the NanoString Technologies, Inc. ("NanoString") transaction ($0.4 million). For the three months ended September 30, 2025, adjustments consist primarily of transaction-related expenses associated with contingent consideration related to NanoString and contingent consideration associated with the acquisition of C2i Genomics. For the nine months ended September 30, 2026, adjustments consist primarily of transaction-related expenses associated with the acquisition of Convergent ($1.7 million) partially offset with NanoString contingent consideration ($1.1 million). For the nine months ended September 30, 2025, adjustments consist primarily of transaction-related expenses associated with the acquisition of C2i Genomics ($1.6 million) partially offset by NanoString contingent consideration ($1.0 million). 2.For the three months ended September 30, 2026, adjustments consist primarily of expenses related to legal proceedings ($3.2 million), partially offset by the impact of Non-GAAP adjustments on IT/Facilities allocations ($0.3 million). For the three months ended September 30, 2025, adjustments primarily include a vendor legal settlement ($2.8 million) partially offset by expenses related to the restructuring and liquidation proceedings of Veracyte SAS ($1.0 million) and other legal proceedings ($0.5 million). For the nine months ended September 30, 2026, adjustments consist primarily of expenses related to legal proceedings ($4.9 million), expenses related to the assessment of licensing and strategic investments ($3.0 million), and expenses related to the liquidation proceedings of Veracyte SAS ($0.3 million), partially offset by the impact of Non-GAAP adjustments on IT/Facilities allocations ($0.9 million). For the nine months ended September 30, 2025, adjustments include additional expenses related to Veracyte SAS impairment loss ($20.5 million) and related to the restructuring and liquidation proceedings of Veracyte SAS ($8.0 million), partially offset by adjustments related to restructuring costs ($0.1 million).

1.Includes transaction-related expenses as well as post-combination compensation expenses. For the three months ended September 30, 2026, adjustments consist primarily of transaction-related expenses associated with the acquisition activities ($1.9 million), partially offset by contingent consideration related to the NanoString transaction ($0.4 million). For the three months ended September 30, 2025, adjustments consist primarily of transaction-related expenses associated with contingent consideration related to NanoString and contingent consideration associated with the acquisition of C2i Genomics. For the nine months ended September 30, 2026, adjustments consist primarily of transaction-related expenses associated with the acquisition activities ($1.9 million), partially offset with NanoString contingent consideration ($1.1 million). For the nine months ended September 30, 2025, adjustments consist primarily of transaction-related expenses associated with the acquisition of C2i Genomics ($1.6 million) partially offset by NanoString contingent consideration ($1.0 million). 2.Includes interest income and income related to research tax credits. 3.For the three months ended September 30, 2026, adjustments consist primarily of expenses related to legal proceedings ($3.2 million). For the three months ended September 30, 2025, adjustments primarily include expenses related to the exclusion of unrealized loss related to Veracyte SAS deconsolidation ($6.7 million), the exclusion of unrealized loss associated with foreign exchange impact on stock-based compensation and intercompany loans ($1.3 million), the restructuring and liquidation proceedings of Veracyte SAS ($2.4 million), and other legal proceedings ($0.5 million), partially offset by vendor legal settlement ($2.8 million). For the nine months ended September 30, 2026, adjustments primarily include expenses related to legal proceedings ($4.9 million), expenses related to the assessment of licensing and strategic investments ($3.0 million), expenses related to the liquidation proceedings of Veracyte SAS ($0.3 million), and losses related to asset disposition ($0.4 million), partially offset by adjustments related to the restructuring and liquidation proceedings of Veracyte SAS ($4.2 million). For the nine months ended September 30, 2025, adjustments include additional expenses related to Veracyte SAS impairment loss ($20.5 million) and Veracyte SAS investment review ($8.0 million), partially offset by adjustments related to restructuring costs ($0.1 million) and additional exclusion of unrealized gains associated with foreign exchange impacts on stock-based compensation and intercompany loans ($3.6 million). 4.Incremental non-GAAP tax expense reflects the tax impact of the non-GAAP adjustments listed. 5.In those periods in which GAAP net (loss) income is negative and non-GAAP net (loss) income is positive, non-GAAP diluted weighted average shares outstanding includes potentially dilutive common shares from equity awards as determined using the treasury stock method.

Full text with the tables
                                                                    Exhibit 99.1
                                                                                
            Veracyte Announces Third Quarter 2026 Financial Results             
                                                                                
  Grew total revenue to $151.8 million and testing revenue to $146.4 million,   
                     representing 15% year-over-year growth                     
                                                                                
                Announces $100 million share repurchase program                 
SOUTH SAN FRANCISCO, Calif., November 4, 2026 --- Veracyte, Inc. (Nasdaq: VCYT),
a leading cancer diagnostics company, today announced financial results for the
third quarter ended September 30, 2026.

“We delivered solid third quarter results supported by strong profitability and
cash generation,” said Marc Stapley, chief executive officer of Veracyte.
“Afirma outperformed, while Decipher Prostate volume was below our expectations.
We remain confident in the long-term outlook of our business and expect a number
of evidence-based catalysts to support growth in our core franchises while also
advancing our breast and bladder strategies. As we execute on these
opportunities, our differentiated financial profile enables us to continue
investing in the business to drive long-term growth.”
                                                                                
  Key Financial Highlights                                                      
                                                                                
For the three-month period ended September 30, 2026, as compared to the same
period in 2025:
• Increased total revenue by 15% to $151.8 million and testing revenue by 15% to
$146.4 million, driven by Decipher Prostate growth of 12% to $92.3 million and
Afirma growth of 19% to $51.5 million.

• Increased total volume by 15% to 52,744 tests and testing volume by 13% to
49,498 tests, driven by approximately 29,900 Decipher Prostate tests, as well as
approximately 19,100 Afirma tests. Volume for each test grew 12% year-over-year.

• Increased product revenue by 40% to $4.6 million, driven by strong adoption of
Prosigna IVD following the release of the phase III OPTIMA trial results at
ASCO.

• Recorded GAAP net income of $31.5 million, or 20.8% of revenue, and delivered
adjusted EBITDA of $41.2 million, or 27.2% o f revenue.

• Generated $40.3 million of cash from operations to end the quarter with $370.5
million of cash, cash equivalents, and short-term investments as of September
30, 2026.
                                                                                
   Key Business Highlights                                                      
                                                                                
• Acquired Convergent Genomics, Inc., expanding our urology portfolio with a
urinary tumor DNA testing platform to help guide bladder cancer care across the
patient journey.

• Secured Medicare reimbursement for our Prosigna Breast Risk of Recurrence
(ROR) test in the U.S. for eligible patients diagnosed with early-stage hormone-
receptor positive (HR+) breast cancer.

• Further expanded the clinical evidence of the Decipher Prostate test, with new
predictive evidence supporting its use with treatment intensification decisions
across intermediate-risk and very high-risk prostate cancer.

• Surpassed a key milestone, with more than 1 million patients served to date
with Veracyte's tests.

• Announced that the Board of Directors has authorized a share repurchase
program for up to $100 million of common stock.

A reconciliation of GAAP to non-GAAP financial measures has been provided in the
tables included in this press release. An explanation of these measures is also
included below under the heading "Note Regarding Use of Non-GAAP Financial
Measures."
                                                                                
  Third Quarter 2026 Financial Results                                          
                                                                                
Total revenue for the third quarter of 2026 was $151.8 million, an increase of
15% compared to $131.9 million reported in the third quarter of 2025. Testing
revenue was $146.4 million, an increase of 15% compared to $127.8

million in the third quarter of 2025, driven by growth in our Decipher Prostate
and Afirma tests. Product revenue was $4.6 million, an increase of 40% compared
to $3.3 million in the third quarter of 2025, driven by strong adoption of
Prosigna IVD following the release of the phase III OPTIMA trial results at
ASCO. Biopharmaceutical and other revenue was $0.7 million, compared to $0.8
million in the third quarter of 2025.

Total gross margin for the third quarter of 2026 was 71%, compared to 69% in the
third quarter of 2025. Non-GAAP gross margin was 74%, compared to 73% in the
third quarter of 2025.

Operating expenses were $90.5 million for the third quarter of 2026 compared to
$68.3 million in the third quarter of 2025. Non-GAAP operating expenses grew 24%
to $72.9 million compared to $58.6 million in the third quarter of 2025.

GAAP Net income for the third quarter of 2026 was $31.5 million, an increase of
$12.4 million compared to the third quarter of 2025. Diluted net earnings per
common share was $0.38, an improvement of $0.14 compared to the third quarter of
2025. Non-GAAP diluted net earnings per common share was $0.51, flat compared to
the third quarter of 2025. Net cash provided by operating activities in the
first nine months of 2026 was $121.3 million, an improvement of $37.6 million
compared to the same period in 2025.

Adjusted EBITDA for the third quarter of 2026 was $41.2 million, an improvement
of 4% compared to the third quarter of 2025, representi ng 27.2% of revenue.
                                                                                
  2026 Financial Outlook                                                        
                                                                                
Veracyte now expects 2026 total revenue guidance of $590 million to $593
million, representing 14% to 15% growth, compared to prior guidance of $590
million to $596 million. This reflects testing revenue of $571 million to $573
million, representing 16% growth, compared to prior guidance of $576 million to
$582 million, with minimal revenue contribution from recently launched tests.
Further, the company continues to expect adjusted EBITDA margin of greater than
26% for 2026.

The company is unable to provide a quantitative reconciliation of expected
adjusted EBITDA margin to expected GAAP net income margin, the most directly
comparable forward-looking GAAP measure without unreasonable effort, because of
the inherent difficulty in accurately forecasting the occurrence and financial
impact of the various adjusting items necessary for such reconciliations that
have not yet occurred, that are dependent on various factors, are out of the
company’s control, or that cannot be reasonably predicted. Such adjustments
include, but are not limited to, acquisition-related expenses, and other
adjustments. Any associated estimate of these items and their impact on GAAP
performance for the guidance period could vary materially. For more information
on the non-GAAP financial measures, please refer to the section titled “Note
Regarding Use of Non-GAAP Financial Measures” at the end of this press release.
                                                                                
  Share Repurchase Program                                                      
                                                                                
Veracyte announced today that its Board of Directors has authorized a share
repurchase program for up to $100 million of its common stock. Under the
repurchase program, the company may repurchase shares through open market
purchases, privately negotiated transactions or by other methods from time to
time. Any open market repurchases will be structured to comply with applicable
federal securities laws, including the pricing and volume requirements of Rule
10b-18 under the Securities Exchange Act of 1934, as amended. The timing,
manner, price, and amount of any repurchases will be determined at the company's
discretion based on a variety of factors, including market conditions, the
trading price of the company's common stock, the company's financial condition
and results of operations, capital requirements, general business conditions,
alternative investment opportunities, and other factors the company deems
relevant. The repurchase program does not obligate the company to acquire any
specific number of shares, may be modified, suspended, or discontinued at any
time without prior notice at the discretion of the Board of Directors, and will
expire after 12 months. The company currently expects to fund the repurchase
program from available cash and cash equivalents.
                                                                                
  Conference Call and Webcast Details                                           
                                                                                
Veracyte will host a conference call and webcast today at 4:30 p.m. Eastern Time
to discuss the company's financial results and provide a general business
update. The conference call will be webcast live from the company’s website and
will be available via the following link: https://edge.media-
server.com/mmc/p/kgcmbvpd. The webcast should be accessed 10 minutes prior to
the conference call start time. A replay of the webcast will be available for
one year following the conclusion of the live broadcast and will be accessible
on the company’s website at https://investor.veracyte.com/events-presentations.
                                                                                
  About Veracyte                                                                
                                                                                
Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to
transform cancer care for patients around the world. The company’s molecular
tests assess the unique biology of each patient’s tumor to help clinicians
answer essential questions about cancer care. Veracyte’s Diagnostics Platform
combines broad genomic and clinical data, advanced bioinformatics and AI, and a
powerful evidence-generation engine to support continued innovation and pipeline
development . The company’s portfolio includes the Afirma® Genomic Sequencing
Classifier test , Decipher® Bladder Genomic Classifier test , Decipher® Prostate
Genomic Classifier test , Prosigna® Breast Risk of Recurrence test , and the
TrueMRD™ Monitoring Test for MIBC . For more information, visit Veracyte’s
website or follow the company on LinkedIn or X (Twitter) .

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not
limited to our statements related to our plans, objectives, and expectations
(financial and otherwise), including with respect to our 2026 financial and
operating results; our share repurchase program, including the timing, amount
and source of funds for any

repurchases of shares; and our intentions with respect to the development,
launch, commercialization, adoption, and reimbursement of our tests and
products. Forward-looking statements can be identified by words such as:
“appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,”
“could,” “would,” “will,” “enable,” “positioned,” “offers,” “designed,”
“ultimately,” “strategic,” “outlook,” “guidance,” and similar references to
future periods. Actual results may differ materially from those projected or
suggested in any forward-looking statements. These statements involve risks and
uncertainties, which could cause actual results to differ materially from our
predictions, and include, but are not limited to: our ability to launch,
commercialize and receive reimbursement for our products; our ability to execute
on our business strategies relating to our acquisitions, including C2i Genomics
and Convergent Genomics, Inc., integration of the business and the realization
of expected benefits and synergies; our ability to demonstrate the validity and
utility of our genomic tests and biopharma and other offerings; our ability to
continue executing on our business plan; our ability to continue to scale our
global operations and enhance our internal control environment; the impact of
the war in Ukraine and other regional conflicts on European economies; the
impact of foreign currency fluctuations, volatile interest rates, inflation, the
impact of legislation and policies enacted by the current U.S. administration;
turmoil in the global banking and finance system; the ongoing conflict in the
Middle East; and the performance and utility of our tests in the clinical
environment. Additional factors that may impact these forward-looking statements
can be found under the caption “Risk Factors” in our Annual Report on Form 10-K
filed on February 26, 2026, as well as in other documents that we may file from
time to time with the Securities and Exchange Commission. Copies of these
documents, when available, may be found in the Investors section of our website
at investor.veracyte.com. These forward-looking statements speak only as of the
date hereof and, except as required by law, we specifically disclaim any
obligation to update these forward-looking statements, whether as a result of
new information, future events or otherwise.
                                                                                
  Note Regarding Use of Non-GAAP Financial Measures                             
                                                                                
In addition to the financial measures prepared in accordance with generally
accepted accounting principles (GAAP), this press release and the accompanying
tables contain, and reference certain non-GAAP results including non-GAAP gross
margin, non-GAAP operating expenses, adjusted EBITDA, adjusted EBITDA as a
percentage of revenue (also referred to as adjusted EBITDA margin), non-GAAP net
income, and non-GAAP earnings per share (EPS) and non-GAAP weighted average
shares outstanding. These non-GAAP financial measures are not meant to be
considered superior to or a substitute for financial measures calculated in
accordance with GAAP, and investors are cautioned that there are material
limitations associated with the use of non-GAAP financial measures as an
analytical tool.

We use non-GAAP financial measures to internally evaluate and analyze financial
results. We believe these non-GAAP financial measures provide investors with
useful supplemental information about the financial performance of our business,
enable comparison of financial results between periods where certain items may
vary independent of business performance, and enable comparison of our financial
results with other public companies, many of which present similar non-GAAP
financial measures. However, the non-GAAP financial measures we present may be
different from those used by other companies, including similarly titled
measures.

We compute these non-GAAP measures by adjusting the applicable GAAP measure to
remove the impact of certain recurring and non-recurring charges and gains and
to adjust for the impact of income tax items related to such adjustments to our
GAAP financial statements. In particular, we exclude amortization of acquired
intangible assets,

acquisition-related expenses relating to our acquisitions of Decipher
Biosciences, HalioDx and C2i Genomics, impairment charges associated with the
nCounter license and other biopharmaceutical services related to HalioDx
intangible assets, all stock-based compensation and certain costs related to
restructuring from all of our non-GAAP financial measures as well as
depreciation and income tax items from our adjusted EBITDA and adjusted EBITDA
as a percentage of revenue. Beginning in the second quarter of 2024, we changed
our non-GAAP policy to exclude all stock-based compensation to align with our
peers and we have also excluded all stock-based compensation from our prior
period non-GAAP financial measures. Management has excluded the effects of these
items in non-GAAP financial measures to help investors gain a better
understanding of the core operating results and future prospects of the company,
consistent with how management measures and forecasts the company's performance,
especially when comparing such results to previous periods or forecasts. The
company encourages investors to carefully consider its results under GAAP,
together with its supplemental non‐GAAP information and the reconciliation
between these presentations. See “Reconciliation of U.S. GAAP to Non-GAAP
Financial Measures” for a reconciliation of each non-GAAP measure presented to
the comparable GAAP financial measure.
                                                                                
  VERA…                                                                         
  INC.                                                                          
  COND…                                                                         
  CONS…                                                                         
  STAT…                                                                         
  OF                                                                            
  OPER…                                                                         
  (Una…                                                                         
  (In                                                                           
  thou…                                                                         
  exce…                                                                         
  share    Three                              Nine                              
  and      Months                             Months                            
  per      Ended                              Ended                             
  share    Septe…                             Septem…                           
  amou…    30,                                30,                               
  Reve…    2026               2025            2026               2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Test…    $       146,419    $     127,7…    $        427,1…    $     357,328  
  reve…                                                                         
  Prod…              4,626           3,301             12,163           10,479  
  reve…                                                                         
  Biop…                                                                         
  and                  709             815              1,812            8,702  
  other                                                                         
  reve…                                                                         
  Total            151,754          131,8…             441,1…          376,509  
  reve…                                                                         
  Cost                                                                          
  of                                                                            
  reve…                                                                         
  (1)                                                                           
  Cost                                                                          
  of                38,477          33,777             108,0…           94,444  
  test…                                                                         
  reve…                                                                         
  Cost                                                                          
  of                 2,766           3,015              7,172            6,186  
  prod…                                                                         
  reve…                                                                         
  Cost                                                                          
  of                                                                            
  biop…                142           1,091                357            7,361  
  and                                                                           
  other                                                                         
  reve…                                                                         
  Inta…                                                                         
  asset                                                                         
  amor…                                                                         
  -                  3,265           2,707              8,713            7,959  
  cost                                                                          
  of                                                                            
  reve…                                                                         
  Total                                                                         
  cost              44,650          40,590             124,3…          115,950  
  of                                                                            
  reve…                                                                         
  Gross            107,104          91,282             316,8…          260,559  
  prof…                                                                         
  Oper…                                                                         
  expe…                                                                         
  (1)                                                                           
  Rese…                                                                         
  and               32,159          15,981             88,699           49,965  
  deve…                                                                         
  Sell…                                                                         
  and               28,652          24,455             84,071           74,225  
  mark…                                                                         
  Gene…                                                                         
  and               29,302          27,278             80,425           93,417  
  admi…                                                                         
  Impa…                                                                         
  of                     —               —                  —           20,505  
  asse…                                                                         
  Inta…                                                                         
  asset                                                                         
  amor…                422             622              1,422            1,865  
  -                                                                             
  oper…                                                                         
  expe…                                                                         
  Total                                                                         
  oper…             90,535          68,336             254,6…          239,977  
  expe…                                                                         
  Inco…                                                                         
  from              16,569          22,946             62,195           20,582  
  oper…                                                                         
  Other                                                                         
  inco…              4,553          -4,057             15,424            6,985  
  (los…                                                                         
  net                                                                           
  Inco…                                                                         
  befo…             21,122          18,889             77,619           27,567  
  inco…                                                                         
  taxes                                                                         
  Inco…                                                                         
  tax              -10,381            -248             -8,081            2,363  
  prov…                                                                         
  (ben…                                                                         
  Net      $        31,503    $     19,137    $        85,700    $      25,204  
  inco…                                                                         
  Earn…                                                                         
  per                                                                           
  shar…                                                                         
  Basic    $          0.39    $       0.24    $          1.07    $        0.32  
  Dilu…    $          0.38    $       0.24    $          1.04    $        0.32  
  Shar…                                                                         
  used                                                                          
  to                                                                            
  comp…                                                                         
  earn…                                                                         
  per                                                                           
  comm…                                                                         
  shar…                                                                         
  Basic            80,500…          78,72…             80,00…          78,384…  
  Dilu…            82,783…          79,69…             82,20…          79,946…  
                                                                                
1. Cost of revenue, research and development, sales and marketing and general
and administrative expenses include the following stock-based compensation
related expenses:
                                                                                
                       Three                              Nine                  
                      Months                            Months                  
                       Ended                             Ended                  
                   September                          Septemb…                  
             2026        30,    2025            2026       30,    2025          
 ────────────────────────────────────────────────────────────────────────────── 
  Cost of    $           995    $        540    $        3,054    $      1,668  
  revenue                                                                       
  Resear…                                                                       
  and                  2,742           1,949             8,340           6,023  
  develo…                                                                       
  Selling                                                                       
  and                  2,734           2,102             7,839           6,258  
  market…                                                                       
  General                                                                       
  and                  7,488           6,166            21,573          18,751  
  admini…                                                                       
  Total                                                                         
  stock-…    $        13,959    $     10,757    $       40,806    $     32,700  
  compen…                                                                       
  expense                                                                       
                                                                                
                                                                                
  VERAC…                                                                        
  INC.                                                                          
  CONDE…                                                                        
  CONSO…                                                                        
  STATE…                                                                        
  OF                                                                            
  COMPR…                                                                        
  INCOME                                                                        
  (Unau…                                                                        
  (In                                                                           
  thous…                                                                        
              Three                               Nine                          
             Months                             Months                          
              Ended                              Ended                          
            Septem…                            Septem…                          
                30,                                30,                          
               2026            2025               2026            2025          
  Net             $  31,503       $  19,137          $  85,700       $  25,204  
  income                                                                        
  Other                                                                         
  compr…                                                                        
  income                                                                        
  (loss…                                                                        
  Change                                                                        
  in                                                                            
  curre…               -122          -4,556                151          19,575  
  trans…                                                                        
  adjus…                                                                        
  Relea…                                                                        
  of                                                                            
  accum…                  —           8,295                  —           8,295  
  trans…                                                                        
  adjus…                                                                        
  Other                                                                         
  compr…               -122           3,739                151          27,870  
  income                                                                        
  (loss)                                                                        
  Net                                                                           
  compr…          $  31,381       $  22,876          $  85,851       $  53,074  
  income                                                                        
                                                                                
                                                                                
  VERACYTE, INC.                                                                
  CONDENSED                                                                     
  CONSOLIDATED BALANCE                                                          
  SHEETS                                                                        
  (In thousands)           September 30,               December 31,             
  Assets                   2026                        2025                     
  Current assets:          (Unaudited)                 (See Note 1)             
 ────────────────────────────────────────────────────────────────────────────── 
  Cash and cash            $                199,828    $               362,578  
  equivalents                                                                   
  Short-term                                170,704                     50,311  
  investments                                                                   
  Accounts receivable                        56,788                     44,660  
  Supplies                                   25,818                     20,546  
  Prepaid expenses and                                                          
  other current                              14,740                     10,281  
  assets                                                                        
  Total current assets                      467,878                    488,376  
  Property, plant and                        24,870                     22,192  
  equipment, net                                                                
  Right-of-use assets,                       35,097                     36,599  
  operating leases                                                              
  Intangible assets,                        184,883                     89,148  
  net                                                                           
  Goodwill                                  855,575                    767,154  
  Restricted cash                             1,646                      1,648  
  Other assets                                3,307                        902  
  Total assets             $              1,573,256    $             1,406,019  
  Liabilities and                                                               
  Stockholders’ Equity                                                          
  Current liabilities:                                                          
  Accounts payable         $                  9,710    $                 4,593  
  Accrued liabilities                        60,087                     48,801  
  Current portion of                            864                      1,160  
  deferred revenue                                                              
  Current portion of                                                            
  acquisition-related                         6,734                      1,332  
  contingent                                                                    
  consideration                                                                 
  Current portion of                                                            
  operating lease                             6,814                      4,051  
  liabilities                                                                   
  Total current                              84,209                     59,937  
  liabilities                                                                   
  Deferred tax                                1,616                        646  
  liabilities                                                                   
  Acquisition-related                                                           
  contingent                                 17,245                        257  
  consideration, net of                                                         
  current portion                                                               
  Operating lease                                                               
  liabilities, net of                        33,922                     35,603  
  current portion                                                               
  Other liabilities                           3,000                          —  
  Total liabilities                         139,992                     96,443  
  Total stockholders’                     1,433,264                  1,309,576  
  equity                                                                        
  Total liabilities and                                                         
  stockholders’            $              1,573,256    $             1,406,019  
  equity                                                                        
  1. The condensed                                                              
  consolidated balance                                                          
  sheet at December 31,                                                         
  2025 has been                                                                 
  derived from the                                                              
  audited financial                                                             
  statements at that                                                            
  date included in the                                                          
  company's Annual                                                              
  Report on Form 10-K                                                           
  for                                                                           
  the year ended                                                                
  December 31, 2025,                                                            
  filed                                                                         
  with the Securities                                                           
  and Exchange                                                                  
  Commission on                                                                 
  February 26, 2026.                                                            
                                                                                
                                                                                
  VERACYTE, INC.                                                                
  CONDENSED CONSOLIDATED                                                        
  STATEMENTS OF CASH                                                            
  FLOWS                                                                         
  (Unaudited)               Nine Months Ended                                   
  (In thousands)            September 30,                                       
  Operating activities      2026                                 2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Net income                $                          85,700    $      25,204  
  Adjustments to                                                                
  reconcile net income                                                          
  to                                                                            
  net cash provided by                                                          
  operating                                                                     
  activities:                                                                   
  Depreciation and                                     16,247           16,117  
  amortization                                                                  
  Loss on disposal of                                                           
  property, plant and                                     367               15  
  equipment                                                                     
  Stock-based                                          40,806           32,700  
  compensation                                                                  
  Deferred income taxes                               -11,599              -13  
  Noncash lease expense                                 2,088            2,289  
  Revaluation of                                                                
  acquisition-related                                  -1,110           -2,713  
  contingent                                                                    
  consideration                                                                 
  Effect of foreign                                       -23           -3,845  
  currency on operations                                                        
  Amortization of                                                               
  discount on short-term                               -2,380           -2,619  
  investments                                                                   
  Impairment loss                                           —           20,505  
  Non-cash loss on                                                              
  deconsolidation of                                        —            3,863  
  subsidiary                                                                    
  Changes in operating                                                          
  assets and                                                                    
  liabilities:                                                                  
  Accounts receivable                                 -11,963           -3,858  
  Supplies                                             -3,435           -2,642  
  Prepaid expenses and                                                          
  other current                                        -4,112           -6,416  
  assets                                                                        
  Other assets                                           -771              331  
  Operating lease                                         496           -1,681  
  liabilities                                                                   
  Accounts payable                                      5,522             -547  
  Accrued liabilities                                   5,466            7,034  
  and deferred revenue                                                          
  Net cash provided by                                                          
  operating                                           121,299           83,724  
  activities                                                                    
  Investing activities                                                          
  Business acquisitions,                                                        
  net of cash                                        -153,190                —  
  acquired                                                                      
  Purchase of short-term                             -234,997          -99,998  
  investments                                                                   
  Proceeds from maturity                                                        
  of short-term                                       116,984          102,116  
  investments                                                                   
  Issuance of loan                                     -1,622                —  
  receivable                                                                    
  Purchases of property,                                                        
  plant and                                            -8,155           -5,897  
  equipment                                                                     
  Net cash used in                                   -280,980           -3,779  
  investing activities                                                          
  Financing activities                                                          
  Payment of taxes on                                                           
  vested restricted                                   -17,462          -14,645  
  stock units                                                                   
  Proceeds from the                                                             
  exercise of common                                                            
  stock options and                                    14,493           10,572  
  employee stock                                                                
  purchases                                                                     
  Net cash used in                                     -2,969           -4,073  
  financing activities                                                          
  (Decrease) increase in                                                        
  cash, cash                                         -162,650           75,872  
  equivalents and                                                               
  restricted cash                                                               
  Effect of foreign                                                             
  currency on cash, cash                                 -102              707  
  equivalents and                                                               
  restricted cash                                                               
  Net (decrease)                                                                
  increase in cash, cash                             -162,752           76,579  
  equivalents and                                                               
  restricted cash                                                               
  Cash, cash equivalents                                                        
  and restricted                                      364,226          240,631  
  cash at beginning of                                                          
  period                                                                        
  Cash, cash equivalents                                                        
  and restricted            $                         201,474    $     317,210  
  cash at end of period                                                         
                                                                                
                                                                                
  CASH, CASH EQUIVALENTS                                                        
  AND RESTRICTED                                                                
  CASH                                                                          
  (Unaudited)                                                                   
  (In thousands)                                                                
                               September 30,             December 31,           
                                        2026                     2025           
  Cash and cash equivalents                $  199,828               $  362,578  
  Restricted cash                               1,646                    1,648  
  Total cash, cash                                                              
  equivalents and                          $  201,474               $  364,226  
  restricted cash                                                               
                                                                                
                                                                                
  VER…                                                                          
  INC.                                                                          
  REC…                                                                          
  OF                                                                            
  U.S.                                                                          
  GAAP                                                                          
  to                                                                            
  NON…                                                                          
  FIN…                                                                          
  MEA…                                                                          
  (Un…                                                                          
  (In                                                                           
  tho…                                                                          
  Rec…    Three                               Nine                              
  of      Mont…                               Mont…                             
  Non…    Ended                               Ended                             
  Cost    Sept…                               Sept…                             
  of      30,                                 30,                               
  Rev…    2026               2025             2026              2025            
 ────────────────────────────────────────────────────────────────────────────── 
  GAAP                                                                          
  cost                                                                          
  of      $      38,4…       $     33,…       $      108…       $     94,4…     
  tes…                                                                          
  rev…                                                                          
  Sto…                                                                          
  com…            -994             -555              -3,…             -1,5…     
  exp…                                                                          
  Acq…                                                                          
  rel…            -131                —              -131                 —     
  exp…                                                                          
  (1)                                                                           
  Oth…                                                                          
  adj…            -316                —              -954                 —     
  (2)                                                                           
  Non…                                                                          
  cost                                                                          
  of      $      37,0…       $     33,…       $      103…       $     92,9…     
  tes…                                                                          
  rev…                                                                          
  GAAP                                                                          
  cost                                                                          
  of             2,766             3,0…              7,1…             6,186     
  pro…                                                                          
  rev…                                                                          
  Sto…                                                                          
  com…              -1                —                -2                -2     
  exp…                                                                          
  Acq…                                                                          
  rel…               —                —                 —                 —     
  exp…                                                                          
  (1)                                                                           
  Oth…                                                                          
  adj…               —             -1,…                11             -1,4…     
  (2)                                                                           
  Non…                                                                          
  cost                                                                          
  of      $      2,765       $     1,5…       $      7,1…       $     4,734     
  pro…                                                                          
  rev…                                                                          
  GAAP                                                                          
  cost                                                                          
  of                                                                            
  bio…             142             1,0…               357             7,361     
  and                                                                           
  oth…                                                                          
  rev…                                                                          
  Sto…                                                                          
  com…               —               15                 —              -123     
  exp…                                                                          
  Acq…                                                                          
  rel…               —                —                 —                 —     
  exp…                                                                          
  (1)                                                                           
  Oth…                                                                          
  adj…               —                —                 —                 —     
  (2)                                                                           
  Non…                                                                          
  cost                                                                          
  of                                                                            
  bio…    $        142       $     1,1…       $       357       $     7,238     
  and                                                                           
  oth…                                                                          
  rev…                                                                          
  Rec…                                                                          
  of                                                                            
  Non…                                                                          
  Gro…                                                                          
  Mar…                                                                          
  GAAP                                                                          
  Gro…    $      107,…       $     91,…       $      316…       $     260,…     
  Pro…                                                                          
  GAAP                                                                          
  Gro…            70.6  %          69.2  %           71.8  %           69.2  %  
  Mar…                                                                          
  Amo…                                                                          
  of             3,265             2,7…              8,7…             7,959     
  int…                                                                          
  ass…                                                                          
  Sto…                                                                          
  com…             995              540              3,0…             1,668     
  exp…                                                                          
  Acq…                                                                          
  rel…             131                —               131                 —     
  exp…                                                                          
  (1)                                                                           
  Oth…                                                                          
  adj…             316             1,4…               943             1,450     
  (2)                                                                           
  Non…                                                                          
  Gro…    $      111,…       $     95,…       $      329…       $     271,…     
  Pro…                                                                          
  Non…                                                                          
  Gro…            73.7  %          72.8  %           74.7  %           72.1  %  
  Mar…                                                                          
  1.I…                                                                          
  tra…                                                                          
  exp…                                                                          
  For                                                                           
  the                                                                           
  thr…                                                                          
  mon…                                                                          
  and                                                                           
  nine                                                                          
  mon…                                                                          
  end…                                                                          
  Sep…                                                                          
  30,                                                                           
  202…                                                                          
  adj…                                                                          
  con…                                                                          
  pri…                                                                          
  of                                                                            
  tra…                                                                          
  exp…                                                                          
  ass…                                                                          
  with                                                                          
  acq…                                                                          
  act…                                                                          
  ($0…                                                                          
  2.F…                                                                          
  the                                                                           
  thr…                                                                          
  mon…                                                                          
  end…                                                                          
  Sep…                                                                          
  30,                                                                           
  202…                                                                          
  adj…                                                                          
  inc…                                                                          
  the                                                                           
  imp…                                                                          
  of                                                                            
  Non…                                                                          
  adj…                                                                          
  on                                                                            
  IT/…                                                                          
  all…                                                                          
  ($0…                                                                          
  mil…                                                                          
  For                                                                           
  the                                                                           
  thr…                                                                          
  mon…                                                                          
  end…                                                                          
  Sep…                                                                          
  30,                                                                           
  202…                                                                          
  adj…                                                                          
  inc…                                                                          
  exp…                                                                          
  rel…                                                                          
  to                                                                            
  Ver…                                                                          
  SAS                                                                           
  inv…                                                                          
  rev…                                                                          
  For                                                                           
  the                                                                           
  nine                                                                          
  mon…                                                                          
  end…                                                                          
  Sep…                                                                          
  30,                                                                           
  202…                                                                          
  adj…                                                                          
  inc…                                                                          
  the                                                                           
  imp…                                                                          
  of                                                                            
  Non…                                                                          
  adj…                                                                          
  on                                                                            
  IT/…                                                                          
  all…                                                                          
  ($0…                                                                          
  mil…                                                                          
  par…                                                                          
  off…                                                                          
  by                                                                            
  exp…                                                                          
  rel…                                                                          
  to                                                                            
  the                                                                           
  res…                                                                          
  of                                                                            
  Ver…                                                                          
  SAS.                                                                          
  For                                                                           
  the                                                                           
  nine                                                                          
  mon…                                                                          
  end…                                                                          
  Sep…                                                                          
  30,                                                                           
  202…                                                                          
  adj…                                                                          
  inc…                                                                          
  exp…                                                                          
  rel…                                                                          
  to                                                                            
  Ver…                                                                          
  SAS                                                                           
  inv…                                                                          
  rev…                                                                          
                                                                                
                                                                                
  VERA…                                                                         
  INC.                                                                          
  RECO…                                                                         
  OF                                                                            
  U.S.                                                                          
  GAAP                                                                          
  to                                                                            
  NON-…                                                                         
  FINA…                                                                         
  MEAS…                                                                         
  (Una…                                                                         
  (In                                                                           
  thou…    Three                               Nine                             
  Reco…    Months                              Months                           
  of       Ended                               Ended                            
  Non-…    Septem…                             Septe…                           
  Oper…    30,                                 30,                              
  Expe…    2026               2025             2026               2025          
 ────────────────────────────────────────────────────────────────────────────── 
  GAAP                                                                          
  rese…    $        32,159    $      15,981    $        88,699    $     49,965  
  and                                                                           
  deve…                                                                         
  Stoc…                                                                         
  comp…             -2,742           -1,949             -8,340          -6,023  
  expe…                                                                         
  Acqu…                                                                         
  rela…                 -1                —                 -1               —  
  expe…                                                                         
  (1)                                                                           
  Other                                                                         
  adju…               -176                —               -652               —  
  (2)                                                                           
  Non-…                                                                         
  rese…    $        29,240    $      14,032    $        79,706    $     43,942  
  and                                                                           
  deve…                                                                         
  GAAP                                                                          
  sales    $        28,652    $      24,455    $        84,071    $     74,225  
  and                                                                           
  mark…                                                                         
  Stoc…                                                                         
  comp…             -2,734           -2,102             -7,839          -6,258  
  expe…                                                                         
  Acqu…                                                                         
  rela…                  —                —                  —               —  
  expe…                                                                         
  (1)                                                                           
  Other                                                                         
  adju…                -45                —               -124               —  
  (2)                                                                           
  Non-…                                                                         
  sales    $        25,873    $      22,353    $        76,108    $     67,967  
  and                                                                           
  mark…                                                                         
  GAAP                                                                          
  gene…    $        29,302    $      27,278    $        80,425    $     93,417  
  and                                                                           
  admi…                                                                         
  Stoc…                                                                         
  comp…             -7,488           -6,166            -21,573          -18,7…  
  expe…                                                                         
  Acqu…                                                                         
  rela…             -1,321             -166               -635            -593  
  expe…                                                                         
  (1)                                                                           
  Other                                                                         
  adju…             -2,694            1,308             -6,516          -6,530  
  (2)                                                                           
  Non-…                                                                         
  gene…    $        17,799    $      22,254    $        51,701    $     67,543  
  and                                                                           
  admi…                                                                         
  GAAP                                                                          
  total    $        90,535    $      68,336    $       254,617    $     239,9…  
  oper…                                                                         
  expe…                                                                         
  Amor…                                                                         
  of                  -422             -622             -1,422          -1,865  
  inta…                                                                         
  asse…                                                                         
  Stoc…                                                                         
  comp…             -12,9…          -10,217            -37,752          -31,0…  
  expe…                                                                         
  Acqu…                                                                         
  rela…             -1,322             -166               -636            -593  
  expe…                                                                         
  (1)                                                                           
  Other                                                                         
  adju…             -2,915            1,308             -7,292          -27,0…  
  (2)                                                                           
  Non-…                                                                         
  total    $        72,912    $      58,639    $       207,515    $     179,4…  
  oper…                                                                         
  expe…                                                                         
                                                                                
                                                      
  1.Includes transaction-related expenses as well as  
  post-combination compensation expenses. For the     
  three months ended September 30, 2026, adjustments  
  consist primarily of transaction-related expenses   
  associated with the acquisition of Convergent       
  Genomics, Inc. ("Convergent") ($1.7 million)        
  partially offset with contingent consideration      
  related to the NanoString Technologies, Inc.        
  ("NanoString") transaction ($0.4 million). For the  
  three months ended September 30, 2025, adjustments  
  consist primarily of transaction-related expenses   
  associated with contingent consideration related    
  to NanoString and contingent consideration          
  associated with the acquisition of C2i Genomics.    
  For the nine months ended September 30, 2026,       
  adjustments consist primarily of                    
  transaction-related expenses associated with the    
  acquisition of Convergent ($1.7 million) partially  
  offset with NanoString contingent consideration     
  ($1.1 million). For the nine months ended           
  September 30, 2025, adjustments consist primarily   
  of transaction-related expenses associated with     
  the acquisition of C2i Genomics ($1.6 million)      
  partially offset by NanoString contingent           
  consideration ($1.0 million).                       
  2.For the three months ended September 30, 2026,    
  adjustments consist primarily of expenses related   
  to legal proceedings ($3.2 million), partially      
  offset by the impact of Non-GAAP adjustments on     
  IT/Facilities allocations ($0.3 million). For the   
  three months ended September 30, 2025, adjustments  
  primarily include a vendor legal settlement ($2.8   
  million) partially offset by expenses related to    
  the restructuring and liquidation proceedings of    
  Veracyte SAS ($1.0 million) and other legal         
  proceedings ($0.5 million). For the nine months     
  ended September 30, 2026, adjustments consist       
  primarily of expenses related to legal proceedings  
  ($4.9 million), expenses related to the assessment  
  of licensing and strategic investments ($3.0        
  million), and expenses related to the liquidation   
  proceedings of Veracyte SAS ($0.3 million),         
  partially offset by the impact of Non-GAAP          
  adjustments on IT/Facilities allocations ($0.9      
  million). For the nine months ended September 30,   
  2025, adjustments include additional expenses       
  related to Veracyte SAS impairment loss ($20.5      
  million) and related to the restructuring and       
  liquidation proceedings of Veracyte SAS ($8.0       
  million), partially offset by adjustments related   
  to restructuring costs ($0.1 million).              
                                                      
                                                                                
  VER…                                                                          
  INC.                                                                          
  REC…                                                                          
  OF                                                                            
  U.S.                                                                          
  GAAP                                                                          
  to                                                                            
  NON…                                                                          
  FIN…                                                                          
  MEA…                                                                          
  (Un…                                                                          
  (In     Three                               Nine                              
  tho…    Mont…                               Mont…                             
  Rec…    Ended                               Ended                             
  of      Sept…                               Sept…                             
  Adj…    30,                                 30,                               
  EBI…    2026               2025             2026              2025            
 ────────────────────────────────────────────────────────────────────────────── 
  GAAP                                                                          
  Net     $      31,5…       $     19,…       $      85,…       $     25,2…     
  Inc…                                                                          
  (Lo…                                                                          
  GAAP                                                                          
  Net                                                                           
  Inc…                                                                          
  (Lo…            20.8  %          14.5  %           19.4  %            6.7  %  
  as a                                                                          
  % of                                                                          
  Rev…                                                                          
  Amo…                                                                          
  of             3,687             3,3…              10,…             9,824     
  int…                                                                          
  ass…                                                                          
  Dep…           2,293             1,9…              6,1…             6,293     
  exp…                                                                          
  Sto…                                                                          
  com…           13,9…             10,…              40,…             32,7…     
  exp…                                                                          
  Acq…                                                                          
  rel…           1,453              166               767               593     
  exp…                                                                          
  (1)                                                                           
  Oth…                                                                          
  exp…                                                                          
  (in…           -4,5…             -3,…              -11…             -9,6…     
  net                                                                           
  (2)                                                                           
  Oth…                                                                          
  adj…           3,231             8,1…              4,4…             32,8…     
  (3)                                                                           
  Inc…                                                                          
  tax            -10,…             -248              -8,…             2,363     
  exp…                                                                          
  (be…                                                                          
  Adj…    $      41,2…       $     39,…       $      127…       $     100,…     
  EBI…                                                                          
  Adj…                                                                          
  EBI…                                                                          
  as a            27.2  %          30.1  %           29.0  %           26.6  %  
  % of                                                                          
  Rev…                                                                          
  Rec…                                                                          
  of                                                                            
  Non…                                                                          
  Net                                                                           
  Inc…                                                                          
  (Lo…                                                                          
  GAAP                                                                          
  Net     $      31,5…       $     19,…       $      85,…       $     25,2…     
  Inc…                                                                          
  (Lo…                                                                          
  Amo…                                                                          
  of             3,687             3,3…              10,…             9,824     
  int…                                                                          
  ass…                                                                          
  Sto…                                                                          
  com…           13,9…             10,…              40,…             32,7…     
  exp…                                                                          
  Acq…                                                                          
  rel…           1,453              166               767               593     
  exp…                                                                          
  (1)                                                                           
  Oth…                                                                          
  adj…           3,231             8,1…              4,4…             32,8…     
  (3)                                                                           
  Tax                                                                           
  adj…           -11,…             -565              -13…              -807     
  (4)                                                                           
  Non…                                                                          
  Net     $      41,8…       $     40,…       $      128…       $     100,…     
  Inc…                                                                          
  Rec…                                                                          
  of                                                                            
  Non…                                                                          
  Ear…                                                                          
  per                                                                           
  Sha…                                                                          
  Dil…                                                                          
  ear…                                                                          
  per     $       0.38       $     0.24       $      1.04       $      0.32     
  sha…                                                                          
  GAAP                                                                          
  Amo…                                                                          
  of              0.04             0.04              0.12              0.12     
  int…                                                                          
  ass…                                                                          
  Sto…                                                                          
  com…            0.17             0.13              0.50              0.41     
  exp…                                                                          
  Acq…                                                                          
  rel…            0.02                —              0.01              0.01     
  exp…                                                                          
  (1)                                                                           
  Oth…                                                                          
  adj…            0.04             0.10              0.05              0.41     
  (3)                                                                           
  Tax                                                                           
  adj…           -0.14             -0.…              -0.…             -0.01     
  (4)                                                                           
  Rou…                                                                          
  and                                                                           
  imp…               —             0.01                 —                 —     
  of                                                                            
  dil…                                                                          
  sha…                                                                          
  Dil…                                                                          
  ear…                                                                          
  per     $       0.51       $     0.51       $      1.56       $      1.26     
  sha…                                                                          
  non…                                                                          
  Wei…                                                                          
  ave…                                                                          
  sha…                                                                          
  out…                                                                          
  used                                                                          
  in                                                                            
  com…                                                                          
  dil…                                                                          
  ear…                                                                          
  per                                                                           
  sha…                                                                          
  Dil…           82,7…             79,…              82,…             79,9…     
  GAAP                                                                          
  Dil…                                                                          
  eff…                                                                          
  of                 —                —                 —                 —     
  equ…                                                                          
  awa…                                                                          
  (5)                                                                           
  Dil…           82,7…             79,…              82,…             79,9…     
  non…                                                                          
                                                                                
                                                      
  1.Includes transaction-related expenses as well as  
  post-combination compensation expenses. For the     
  three months ended September 30, 2026, adjustments  
  consist primarily of transaction-related expenses   
  associated with the acquisition activities ($1.9    
  million), partially offset by contingent            
  consideration related to the NanoString             
  transaction ($0.4 million). For the three months    
  ended September 30, 2025, adjustments consist       
  primarily of transaction-related expenses           
  associated with contingent consideration related    
  to NanoString and contingent consideration          
  associated with the acquisition of C2i Genomics.    
  For the nine months ended September 30, 2026,       
  adjustments consist primarily of                    
  transaction-related expenses associated with the    
  acquisition activities ($1.9 million), partially    
  offset with NanoString contingent consideration     
  ($1.1 million). For the nine months ended           
  September 30, 2025, adjustments consist primarily   
  of transaction-related expenses associated with     
  the acquisition of C2i Genomics ($1.6 million)      
  partially offset by NanoString contingent           
  consideration ($1.0 million).                       
  2.Includes interest income and income related to    
  research tax credits.                               
  3.For the three months ended September 30, 2026,    
  adjustments consist primarily of expenses related   
  to legal proceedings ($3.2 million). For the three  
  months ended September 30, 2025, adjustments        
  primarily include expenses related to the           
  exclusion of unrealized loss related to Veracyte    
  SAS deconsolidation ($6.7 million), the exclusion   
  of unrealized loss associated with foreign          
  exchange impact on stock-based compensation and     
  intercompany loans ($1.3 million), the              
  restructuring and liquidation proceedings of        
  Veracyte SAS ($2.4 million), and other legal        
  proceedings ($0.5 million), partially offset by     
  vendor legal settlement ($2.8 million). For the     
  nine months ended September 30, 2026, adjustments   
  primarily include expenses related to legal         
  proceedings ($4.9 million), expenses related to     
  the assessment of licensing and strategic           
  investments ($3.0 million), expenses related to     
  the liquidation proceedings of Veracyte SAS ($0.3   
  million), and losses related to asset disposition   
  ($0.4 million), partially offset by adjustments     
  related to the restructuring and liquidation        
  proceedings of Veracyte SAS ($4.2 million). For     
  the nine months ended September 30, 2025,           
  adjustments include additional expenses related to  
  Veracyte SAS impairment loss ($20.5 million) and    
  Veracyte SAS investment review ($8.0 million),      
  partially offset by adjustments related to          
  restructuring costs ($0.1 million) and additional   
  exclusion of unrealized gains associated with       
  foreign exchange impacts on stock-based             
  compensation and intercompany loans ($3.6           
  million).                                           
  4.Incremental non-GAAP tax expense reflects the     
  tax impact of the non-GAAP adjustments listed.      
  5.In those periods in which GAAP net (loss) income  
  is negative and non-GAAP net (loss) income is       
  positive, non-GAAP diluted weighted average shares  
  outstanding includes potentially dilutive common    
  shares from equity awards as determined using the   
  treasury stock method.                              
                                                      
                                     # # #                                      
Investors:

Kelly Gura

[email protected]

Media:

Molly Cornbleet

[email protected]

+1-650-351-8780

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/VCYT/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.